A clinical trial update for anamorelin was recorded on October 6, 2026. The study, registered as NCT03743051, is titled "A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1."
This is a Phase 3 trial, and its current status is listed as completed. The trial focused on adult patients with advanced non-small cell lung cancer who experience malignancy associated weight loss and anorexia.
Anamorelin remains classified as an unapproved compound under research status. No results, efficacy outcomes, or safety findings are described in this update. The record reflects only a change in trial status to completed as of the stated date.
Readers interested in this trial can consult the registry listing for further procedural details as they become available. For general background on this compound, see the linked compound overview for additional context.